CARDIFF ONCOLOGY, INC. Other Income and Expense
CARDIFF ONCOLOGY, INC. (CRDF) reported Other Income and Expense of $383.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for the quarter ending 2026-06-30 was $383.00K, a 54.08% decline year-over-year.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for the quarter ending 2026-03-31 was $505.00K, a 46.73% decline year-over-year.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for the quarter ending 2025-12-31 was $611.00K, a 22.17% decline year-over-year.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for the quarter ending 2025-09-30 was $716.00K, a 4.02% decline year-over-year.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for fiscal 2025 was $3.11M, a 3.45% decline from fiscal 2024.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for fiscal 2024 was $3.22M, a 18.91% decline from fiscal 2023.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for fiscal 2023 was $3.97M, a 231.47% increase from fiscal 2022.
- CARDIFF ONCOLOGY, INC. nonoperating income (expense) for fiscal 2022 was $1.20M, a 112.41% increase from fiscal 2021.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $383.00K 10-Q · filed 2026-08-11 | $888.00K 10-Q · filed 2026-08-11 | $1.50M derived: sum of 3 quarters · filed 2026-08-11 | $2.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $505.00K 10-Q · filed 2026-05-14 | $1.12M derived: sum of 2 quarters · filed 2026-05-14 | $1.83M derived: sum of 3 quarters · filed 2026-05-14 | $2.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $611.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.33M derived: sum of 2 quarters · filed 2026-02-24 | $2.16M derived: sum of 3 quarters · filed 2026-08-11 | $3.11M 10-K · filed 2026-02-24 |
| 2025-09-30 | $716.00K 10-Q · filed 2025-11-06 | $1.55M derived: sum of 2 quarters · filed 2026-08-11 | $2.50M 10-Q · filed 2025-11-06 | $3.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $834.00K 10-Q · filed 2026-08-11 | $1.78M 10-Q · filed 2026-08-11 | $2.57M derived: sum of 3 quarters · filed 2026-08-11 | $3.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $948.00K 10-Q · filed 2026-05-14 | $1.73M derived: sum of 2 quarters · filed 2026-05-14 | $2.48M derived: sum of 3 quarters · filed 2026-05-14 | $3.25M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $785.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.53M derived: sum of 2 quarters · filed 2026-02-24 | $2.30M derived: sum of 3 quarters · filed 2026-02-24 | $3.22M 10-K · filed 2026-02-24 |
| 2024-09-30 | $746.00K 10-Q · filed 2025-11-06 | $1.51M derived: sum of 2 quarters · filed 2025-11-06 | $2.44M 10-Q · filed 2025-11-06 | $3.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $767.00K 10-Q · filed 2025-07-29 | $1.69M 10-Q · filed 2025-07-29 | $2.68M derived: sum of 3 quarters · filed 2025-07-29 | $3.77M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $922.00K 10-Q · filed 2025-05-08 | $1.92M derived: sum of 2 quarters · filed 2025-05-08 | $3.01M derived: sum of 3 quarters · filed 2025-05-08 | $4.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $995.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.08M derived: sum of 2 quarters · filed 2025-02-27 | $3.14M derived: sum of 3 quarters · filed 2025-02-27 | $3.97M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.09M 10-Q · filed 2024-11-07 | $2.15M derived: sum of 2 quarters · filed 2024-11-07 | $2.98M 10-Q · filed 2024-11-07 | $3.67M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.06M 10-Q · filed 2024-08-08 | $1.89M 10-Q · filed 2024-08-08 | $2.58M derived: sum of 3 quarters · filed 2024-08-08 | $3.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $829.00K 10-Q · filed 2024-05-02 | $1.52M derived: sum of 2 quarters · filed 2024-05-02 | $1.95M derived: sum of 3 quarters · filed 2024-05-02 | $1.95M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $695.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.12M derived: sum of 2 quarters · filed 2024-02-29 | $1.12M derived: sum of 3 quarters · filed 2024-02-29 | $1.20M 10-K · filed 2024-02-29 |
| 2022-09-30 | $422.00K 10-Q · filed 2023-11-02 | $422.00K derived: sum of 2 quarters · filed 2023-11-02 | $503.00K 10-Q · filed 2023-11-02 | $587.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $81.00K 10-Q · filed 2023-08-09 | $165.00K derived: sum of 3 quarters · filed 2023-08-09 | $250.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $81.00K 10-Q · filed 2023-05-04 | $165.00K derived: sum of 2 quarters · filed 2023-05-04 | $250.00K derived: sum of 3 quarters · filed 2023-05-04 | $382.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $169.00K derived: sum of 2 quarters · filed 2023-03-02 | $301.00K derived: sum of 3 quarters · filed 2023-03-02 | $564.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | $85.00K 10-Q · filed 2022-11-03 | $217.00K derived: sum of 2 quarters · filed 2022-11-03 | $480.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $132.00K 10-Q · filed 2022-08-04 | $395.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $263.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$221.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |